- Trials with a EudraCT protocol (184)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
184 result(s) found for: Apolipoprotein A.
Displaying page 1 of 10.
EudraCT Number: 2014-005473-36 | Sponsor Protocol Number: Dezember2014Version2 | Start Date*: Information not available in EudraCT |
Sponsor Name:Universitätsklinikum Freiburg | ||
Full Title: Modeling of lipoprotein in patients with familial hypercholesterolemia compared to healthy subjects | ||
Medical condition: familial hypercholesterolemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000996-98 | Sponsor Protocol Number: CSL112_3001 | Start Date*: 2018-09-05 | |||||||||||
Sponsor Name:CSL Behring LLC | |||||||||||||
Full Title: A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome | |||||||||||||
Medical condition: Acute Coronary Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Temporarily Halted) LV (Completed) SE (Completed) PT (Completed) FI (Completed) BE (Completed) LT (Completed) DK (Completed) EE (Completed) DE (Completed) AT (Completed) CZ (Completed) NO (Completed) HU (Completed) FR (Completed) NL (Completed) ES (Restarted) SK (Completed) BG (Completed) GR (Completed) HR (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003626-26 | Sponsor Protocol Number: 01-05-TL-475-016 | Start Date*: 2006-06-14 | |||||||||||
Sponsor Name:Takeda Europe R&D Centre Ltd | |||||||||||||
Full Title: A double-blind, placebo-controlled, randomized study to evaluate the efficacy and safety of TAK-475 or placebo when co-administered with current lipid-lowering therapy in subjects with homozygous f... | |||||||||||||
Medical condition: Treatment of primary dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001666-10 | Sponsor Protocol Number: 20140415 | Start Date*: 2014-06-24 |
Sponsor Name:Academic Medical Center Amsterdam | ||
Full Title: Local delivery of CER-001 in advanced plaques Proof-of-concept for apoA-1 as initiator of reverse cholesterol transport (LOCATION) | ||
Medical condition: Atherosclerosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-024064-18 | Sponsor Protocol Number: OM-EPA-003 | Start Date*: 2011-03-22 | |||||||||||
Sponsor Name:Omthera Pharmaceutical Inc. | |||||||||||||
Full Title: Efficacy and Safety of Epanova® in Severe Hypertriglyceridemia | |||||||||||||
Medical condition: Severe hypertriglyceridemia defined as serum triglyceride (TG) values ≥500 and <2000 mg/dL (≥5.65 mmol/L and <22.60 mmol/L). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005924-16 | Sponsor Protocol Number: M13-377 | Start Date*: 2012-06-13 | |||||||||||
Sponsor Name:Abbott Laboratories Ireland Limited | |||||||||||||
Full Title: A 12-week, Double-blind, Randomized Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate /Simvastatin 145/20mg and Fenofibrate / Simvastatin 145/40mg Tablets vs. Matching M... | |||||||||||||
Medical condition: Dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002316-24 | Sponsor Protocol Number: TAK-475/EC304 | Start Date*: 2005-09-27 | |||||||||||
Sponsor Name:Takeda Europe R &D Centre Ltd | |||||||||||||
Full Title: A placebo-controlled, double-blind, randomised study to evaluate the efficacy and safety of TAK-475 100mg in subjects with type 2 diabetes currently treated with lipid-lowering therapy. | |||||||||||||
Medical condition: treatment of patients with primary dyslipidaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) FI (Completed) EE (Completed) SK (Completed) CZ (Completed) DE (Completed) DK (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-005438-11 | Sponsor Protocol Number: acth06 | Start Date*: 2005-12-29 |
Sponsor Name:Univ. of Iceland, Dept. Pharmacol. | ||
Full Title: Lipid-lowering effects of ACTH | ||
Medical condition: Healthy male volunteers | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: IS (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001934-19 | Sponsor Protocol Number: LPS14354 | Start Date*: 2016-02-15 | |||||||||||
Sponsor Name:Sanofi-Aventis Groupe | |||||||||||||
Full Title: A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients with Type 2 Diabetes and Mixed Dyslipidemia at High Cardiovascular Ris... | |||||||||||||
Medical condition: Dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) GB (Completed) SE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005995-14 | Sponsor Protocol Number: 3133K1-3001-WW(B2521002) | Start Date*: 2009-05-29 | |||||||||||
Sponsor Name:Wyeth Pharmaceuticals Inc, a wholly owned subsidiary of Pfizer Inc, 500 Arcola road, Collegeville, PA 19426 USA | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects With Mild to Moderate Alzheimer Disea... | |||||||||||||
Medical condition: Alzheimer Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) ES (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005994-79 | Sponsor Protocol Number: 3133K1-3000-WW | Start Date*: 2008-05-13 | |||||||||||
Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development | |||||||||||||
Full Title: Ensayo de fase III, multicéntrico, aleatorizado, en doble ciego, controlado con placebo y de grupos paralelos, sobre la eficacia y la seguridad del bapineuzumab (AAB-001, ELN115727) en pacientes co... | |||||||||||||
Medical condition: Enfermedad de Alzheimer Alzheimer Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) IE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) DE (Prematurely Ended) FR (Completed) FI (Prematurely Ended) SE (Prematurely Ended) IT (Prematurely Ended) SK (Completed) PT (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-001135-85 | Sponsor Protocol Number: AROAPOC3-2003 | Start Date*: 2022-09-06 | |||||||||||
Sponsor Name:Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults with Dyslipidemia | |||||||||||||
Medical condition: Mixed Dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004413-33 | Sponsor Protocol Number: KBT-004 | Start Date*: 2007-10-26 | |||||||||||
Sponsor Name:Karo Bio AB | |||||||||||||
Full Title: A Phase II, Placebo-Controlled, Double-Blind, Randomised, 12-Week, Parallel-group Study to Assess the Efficacy of Different Doses of KB 2115 as add on to Statin Treatment in Patients With Dyslipid... | |||||||||||||
Medical condition: Primary hypercholesterolaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005643-24 | Sponsor Protocol Number: TA-8995-03 | Start Date*: 2013-07-29 | |||||||||||
Sponsor Name:Xention Limited | |||||||||||||
Full Title: A Multi-Centre, Randomised, Double Blind, Placebo Controlled, Parallel Group Study of TA 8995 in Patients with Mild Dyslipidaemia, Alone and In Combination with Statin Therapy | |||||||||||||
Medical condition: Mild dyslipidaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000799-92 | Sponsor Protocol Number: LPS14355 | Start Date*: 2015-12-31 | |||||||||||
Sponsor Name:sanofi-aventis Groupe | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Alirocumab in insulin treated patients with type 1 or type 2 diabetes and with hyperchole... | |||||||||||||
Medical condition: Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) DE (Completed) NL (Completed) AT (Completed) FR (Completed) BE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023611-34 | Sponsor Protocol Number: NLCER-001-CLIN-002 | Start Date*: 2011-05-18 | ||||||||||||||||
Sponsor Name:Cerenis Therapeutics | ||||||||||||||||||
Full Title: A Phase II Multi-Center, Double-Blind, Ascending Dose, Placebo-Controlled, Dose-Finding Trial of CER-001 or Placebo in Subjects with Acute Coronary Syndrome | ||||||||||||||||||
Medical condition: Symptoms of Acute Coronary Syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000893-68 | Sponsor Protocol Number: LAED001 | Start Date*: 2012-11-15 |
Sponsor Name:Fundació Clinic per a la Recerca Biomèdica | ||
Full Title: Differences in endothelial function amongst Sitagliptin and Liraglutide Users: A randomized, open-label, parallel-group and active controlled trial | ||
Medical condition: type 2 diabetes patients not well controlled at the maximum tolerated dose of metformin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2006-005469-20 | Sponsor Protocol Number: DRI6589 | Start Date*: 2007-02-15 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: A randomized, double-blind, parallel-group, placebo-controlled, ezetimibe-calibrated, multicenter study evaluating the safety and efficacy of four doses and two dose-regimens of AVE5530 over 4 week... | |||||||||||||
Medical condition: Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001446-25 | Sponsor Protocol Number: FHGT002 | Start Date*: 2017-09-20 |
Sponsor Name:University of Pennsylvania | ||
Full Title: AAV8-mediated Low Density Lipoprotein Receptor (LDLR) Gene Replacement in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) | ||
Medical condition: Adults with homozygous familial hypercholesterolemia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2022-001109-29 | Sponsor Protocol Number: CKJX839D12304 | Start Date*: 2022-12-06 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients with Primary Hypercholesterolemia Not Receiving Lipid-L... | |||||||||||||
Medical condition: Primary Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
